Related Experiment Video

Updated: Jul 18, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells

Robin L Kilker1, Maricarmen D Planas-Silva

  • 1Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA.

Cancer Research
|December 6, 2006
PubMed

Insights

Cyclin D1 drives tamoxifen-resistant breast cancer cell growth. Blocking cyclin D1 may offer new treatments for tamoxifen-resistant tumors, improving outcomes for patients with hormone-responsive breast cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Tamoxifen is effective for hormone-responsive breast cancer but resistance develops.
  • Understanding resistance mechanisms is crucial for developing new therapies.

Purpose of the Study:

  • Investigate the role of cyclin D1 in tamoxifen-resistant breast cancer cell growth.
  • Identify potential therapeutic targets for overcoming tamoxifen resistance.

Main Methods:

  • Utilized a cell culture model of acquired tamoxifen resistance.
  • Examined the effects of tamoxifen, 4-hydroxytamoxifen (OHT), and ICI 182,780 on cell cycle progression.
  • Assessed cyclin D1 expression and cell proliferation following small interfering RNA (siRNA) knockdown and pharmacologic inhibition of key signaling pathways (PI3K/Akt, MAPK/ERK1/2).

Main Results:

  • Tamoxifen and OHT promoted cell cycle progression in resistant cells after growth arrest.
  • Cyclin D1 downregulation blocked basal and OHT-induced proliferation of resistant cells.
  • Inhibition of PI3K/Akt or MAPK/ERK1/2 pathways reduced cyclin D1 expression and impaired OHT-mediated cell cycle progression.

Conclusions:

  • Cyclin D1 expression is essential for the proliferation of tamoxifen-resistant breast cancer cells.
  • Targeting cyclin D1 may be a viable strategy to inhibit the growth of tamoxifen-resistant tumors.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry11:23

Measuring Cell Cycle Progression Kinetics with Metabolic Labeling and Flow Cytometry

Published on: May 22, 2012

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...